United Therapeutics: First patient enrolled in Phase 3 TETON PPF study

United Therapeutics announced that the first patient has enrolled in the registration-phase TETON PPF study, which will evaluate nebulized Tyvaso Inhalation Solution in 698 adult patients with progressive pulmonary fibrosis. This is in addition to two separate ongoing registration-phase studies, TETON 1 and TETON 2, of nebulized Tyvaso in patients with another type of pulmonary fibrosis known as idiopathic pulmonary fibrosis. The 52-week study will evaluate the impact of nebulized Tyvaso on a key prognostic indicator for PPF known as forced vital capacity. PPF is a progressive form of interstitial lung disease characterized by the loss of the ability of the lungs to transfer oxygen into the blood, ultimately resulting in respiratory failure and death.